Risk of recurrent venous thromboembolism according to baseline risk factor profiles

The optimal duration of anticoagulation for venous thromboembolism (VTE) is uncertain. In this prespecified analysis, we used data from 2 randomized trials, which compared once-daily rivaroxaban (20 mg or 10 mg) with aspirin (100 mg) or placebo for extended VTE treatment to estimate the risk of recu...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Blood Adv
Main Authors: Prins, Martin H., Lensing, Anthonie W. A., Prandoni, Paolo, Wells, Philip S., Verhamme, Peter, Beyer-Westendorf, Jan, Bauersachs, Rupert, Bounameaux, Henri, Brighton, Timothy A., Cohen, Alexander T., Davidson, Bruce L., Decousus, Hervé, Kakkar, Ajay K., van Bellen, Bonno, Pap, Akos F., Homering, Martin, Tamm, Miriam, Weitz, Jeffrey I.
Formato: Artigo
Idioma:Inglês
Publicado: American Society of Hematology 2018
Assuntos:
Thrombosis and Hemostasis
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5894264/
https://ncbi.nlm.nih.gov/pubmed/29632234
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2018017160
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares